{
    "PMC8668943_3": [
        {
            "subject": {
                "Study Type": "Perinatal HIV-1 acquisition",
                "Gene": "FCGR2C",
                "Copy Number": "1",
                "Total Group": "",
                "Effect": "Reduced odds of HIV-1 acquisition",
                "Metric": "P-value"
            },
            "measures": "[Odds Ratio, Confidence Interval, P-value]",
            "outcomes": "[0.29, 0.12-0.71, 0.007]"
        },
        {
            "subject": {
                "Study Type": "Perinatal HIV-1 acquisition",
                "Gene": "FCGR2C",
                "Copy Number": "1",
                "Total Group": "",
                "Effect": "Reduced odds of HIV-1 acquisition",
                "Metric": "P-value"
            },
            "measures": "[Adjusted Odds Ratio, Confidence Interval, P-value]",
            "outcomes": "[0.37, 0.15-0.90, 0.029]"
        },
        {
            "subject": {
                "Study Type": "Perinatal HIV-1 acquisition",
                "Gene": "FCGR2C",
                "Copy Number": "\u22653",
                "Total Group": "",
                "Effect": "No significant association with HIV-1 acquisition",
                "Metric": "P-value"
            },
            "measures": "[Odds Ratio, Confidence Interval, P-value]",
            "outcomes": "[0.99, 0.63-1.57, 0.978]"
        },
        {
            "subject": {
                "Study Type": "Perinatal HIV-1 acquisition",
                "Gene": "FCGR2C",
                "Copy Number": "\u22653",
                "Total Group": "",
                "Effect": "No significant association with HIV-1 acquisition",
                "Metric": "P-value"
            },
            "measures": "[Adjusted Odds Ratio, Confidence Interval, P-value]",
            "outcomes": "[0.74, 0.43-1.27, 0.275]"
        },
        {
            "subject": {
                "Study Type": "Perinatal HIV-1 acquisition",
                "Gene": "FCGR2C",
                "Copy Number": "2",
                "Total Group": "",
                "Effect": "Reference group",
                "Metric": "P-value"
            },
            "measures": "[Odds Ratio, Confidence Interval, P-value]",
            "outcomes": "[Ref, -, -]"
        },
        {
            "subject": {
                "Study Type": "Perinatal HIV-1 acquisition",
                "Gene": "FCGR2C",
                "Copy Number": "2",
                "Total Group": "",
                "Effect": "Reference group",
                "Metric": "P-value"
            },
            "measures": "[Adjusted Odds Ratio, Confidence Interval, P-value]",
            "outcomes": "[Ref, -, -]"
        },
        {
            "subject": {
                "Caption": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition, adjusting for birthweight and FCGR2C genotypes",
                "Metric": "Effect on HIV-1 Acquisition"
            },
            "measures": "[Study Type, Gene, Copy Number Distribution, Effect on HIV-1 Acquisition]",
            "outcomes": "[Perinatal HIV-1 acquisition, FCGR2C, CNR1, adjusting for birthweight and FCGR2C genotypes]"
        },
        {
            "subject": {
                "Footnote": "OR, Odds Ratio; CI, Confidence Interval; PBonf, Bonferroni corrected P value",
                "Metric": "P-value Threshold"
            },
            "measures": "[Statistical Significance, P-value Threshold]",
            "outcomes": "[P < 0.05, 0.05]"
        }
    ],
    "PMC5817808_2": [
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "infant mortality": "2.58%",
                "feeding option": "ERF",
                "mode of feeding": "ERF"
            },
            "measures": "[infant mortality, p-value]",
            "outcomes": "[2.58%, 0.032]"
        },
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "feeding option": "EBF",
                "mode of feeding": "EBF"
            },
            "measures": "[infant mortality, p-value]",
            "outcomes": "[2.45%, 0.032]"
        },
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "feeding option": "MF",
                "mode of feeding": "MF"
            },
            "measures": "[infant mortality, p-value]",
            "outcomes": "[13.33%, 0.032]"
        },
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "HIV status": "Positive"
            },
            "measures": "[Hazard Ratio, p-value]",
            "outcomes": "[0.31, 0.032]"
        },
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "HIV status": "Negative"
            },
            "measures": "[Hazard Ratio, p-value]",
            "outcomes": "[Ref, Ref]"
        },
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "birth weight": ">=2500 g"
            },
            "measures": "[Hazard Ratio, p-value]",
            "outcomes": "[0.88, 0.80]"
        },
        {
            "subject": {
                "study population": "HIV exposed infants of the Essos hospital center PMTCT program",
                "birth weight": "<2500 g"
            },
            "measures": "[Hazard Ratio, p-value]",
            "outcomes": "[Ref, Ref]"
        }
    ],
    "PMC5574138_3": [
        {
            "subject": {
                "Covariate": "Length of follow-up",
                "Estimate": "-0.0138",
                "S.E": "0.0666",
                "95%CI": "(-0.1322, 0.1046)",
                "Regression model": "constructed for covariates, length of follow-up, median CD4 cell counts, median age, and year of publication, and proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[-0.0138]"
        },
        {
            "subject": {
                "Covariate": "Median CD4 count",
                "Estimate": "0.0034",
                "S.E": "0.0066",
                "95%CI": "(-0.0150, 0.0079)",
                "Regression model": "constructed for covariates, length of follow-up, median CD4 cell counts, median age, and year of publication, and proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[0.0034]"
        },
        {
            "subject": {
                "Covariate": "Median age",
                "Estimate": "0.0415",
                "S.E": "0.0503",
                "95%CI": "(-0.1013, 0.0755)",
                "Regression model": "constructed for covariates, length of follow-up, median CD4 cell counts, median age, and year of publication, and proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[0.0415]"
        },
        {
            "subject": {
                "Covariate": "Year of publication",
                "Estimate": "0.0637",
                "S.E": "0.0815",
                "95%CI": "(-0.1736, 0.0980)",
                "Regression model": "constructed for covariates, length of follow-up, median CD4 cell counts, median age, and year of publication, and proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[0.0637]"
        },
        {
            "subject": {
                "Covariate": "Female proportion",
                "Estimate": "-0.5305",
                "S.E": "1.4575",
                "95%CI": "(-3.6792, 2.6183)",
                "Regression model": "constructed for covariates, length of follow-up, median CD4 cell counts, median age, and year of publication, and proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[-0.5305]"
        },
        {
            "subject": {
                "Meta regression": "performed",
                "Association": "significant",
                "Independent variables": "study",
                "Dependent variable": ""
            },
            "measures": "[Association]",
            "outcomes": "[significant]"
        },
        {
            "subject": {
                "Citation": "Meta regression",
                "Study": "versus",
                "Dependent variable": ""
            },
            "measures": "[Study]",
            "outcomes": "[versus]"
        }
    ],
    "PMC4794224_2": [
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DL1",
                "N": "966",
                "%": "97%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DL3",
                "N": "719",
                "%": "72%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DL4",
                "N": "993",
                "%": "100%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DL5",
                "N": "547",
                "%": "55%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DL2*004",
                "N": "31",
                "%": "3%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DL2*001/2/3/5",
                "N": "544",
                "%": "55%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DP1",
                "N": "964",
                "%": "97%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DS1",
                "N": "548",
                "%": "55%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DS2",
                "N": "581",
                "%": "59%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DS3",
                "N": "401",
                "%": "40%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DS4",
                "N": "993",
                "%": "100%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "2DS5",
                "N": "281",
                "%": "28%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "3DL1",
                "N": "929",
                "%": "94%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "3DL2",
                "N": "993",
                "%": "100%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "3DL3",
                "N": "993",
                "%": "100%"
            }
        },
        {
            "subject": {
                "Table": "2",
                "Caption": "Frequency of KIR alleles",
                "Citation": "Distribution of KIR alleles, centromeric, telomeric and combined Cent/Tel alleles and combined KIR/HLA alleles in the studied cohort",
                "KIR Genotypes": "3DS1",
                "N": "354",
                "%": "36%"
            }
        }
    ],
    "PMC9077443_2": [
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "HIV incidence": "0.20 per 100 person-years",
                "95% CI": "0.06\u20130.52"
            },
            "measures": "[HIV incidence]",
            "outcomes": "[0.20 per 100 person-years]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "TDF-FTC",
                "HIV incidence": "1.85 per 100 person-years",
                "95% CI": "1.3\u20132.57"
            },
            "measures": "[HIV incidence]",
            "outcomes": "[1.85 per 100 person-years]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "events per total PY": "36/1942 (1.85%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0.20%, 1.85%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "HR (95% CI)": "0.12 (0.05\u20130.31)",
                "p value": "<0.0001"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.12 (0.05\u20130.31)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "TDF-FTC",
                "HR (95% CI)": "0.12 (0.05\u20130.31)",
                "p value": "<0.0001"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.12 (0.05\u20130.31)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "age": "<25 years",
                "events per total PY": "20/851 (2.34%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0.35%, 2.34%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "age": "\u226525 years",
                "events per total PY": "16/1091 (1.47%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0.09%, 1.47%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "contraceptive method": "DMPA",
                "events per total PY": "21/1000 (2.10%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0.30%, 2.10%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "contraceptive method": "NET-EN",
                "events per total PY": "6/182 (3.30%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0.57%, 3.30%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "contraceptive method": "Implant",
                "events per total PY": "8/607 (1.32%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0%, 1.32%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "contraceptive method": "Other",
                "events per total PY": "1/152 (0.66%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0%, 0.66%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "body-mass index": "\u226430 kg/m<sup>2</sup>",
                "events per total PY": "27/1447 (1.87%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0.29%, 1.87%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "cabotegravir",
                "body-mass index": ">30 kg/m<sup>2</sup>",
                "events per total PY": "9/495 (1.82%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[0%, 1.82%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "TDF-FTC",
                "body-mass index": "\u226430 kg/m<sup>2</sup>",
                "events per total PY": "36/1942 (1.85%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[1.87%, 1.85%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "analysis group": "TDF-FTC",
                "body-mass index": ">30 kg/m<sup>2</sup>",
                "events per total PY": "36/1942 (1.85%)"
            },
            "measures": "[events per total PY]",
            "outcomes": "[1.82%, 1.85%]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.12 (0.05\u20130.31)",
                "p value": "<0.0001"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.12 (0.05\u20130.31)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.16 (0.05\u20130.54)",
                "p value": "0.53"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.16 (0.05\u20130.54)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.09 (0.02\u20130.49)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.09 (0.02\u20130.49)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.16 (0.05\u20130.53)",
                "p value": "0.47"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.16 (0.05\u20130.53)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.05 (0.00\u20130.96)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.05 (0.00\u20130.96)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.22 (0.03\u20131.48)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.22 (0.03\u20131.48)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.06 (0.00\u20131.16)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.06 (0.00\u20131.16)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.32 (0.01\u20139.89)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.32 (0.01\u20139.89)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.17 (0.05\u20130.54)",
                "p value": "0.53"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.17 (0.05\u20130.54)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.09 (0.02\u20130.49)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.09 (0.02\u20130.49)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.16 (0.05\u20130.53)",
                "p value": "0.47"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.16 (0.05\u20130.53)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.05 (0.00\u20130.96)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.05 (0.00\u20130.96)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.22 (0.03\u20131.48)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.22 (0.03\u20131.48)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.06 (0.00\u20131.16)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.06 (0.00\u20131.16)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.32 (0.01\u20139.89)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.32 (0.01\u20139.89)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.17 (0.05\u20130.54)",
                "p value": "0.53"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.17 (0.05\u20130.54)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.09 (0.02\u20130.49)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.09 (0.02\u20130.49)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.16 (0.05\u20130.53)",
                "p value": "0.47"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.16 (0.05\u20130.53)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.05 (0.00\u20130.96)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.05 (0.00\u20130.96)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.22 (0.03\u20131.48)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.22 (0.03\u20131.48)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.06 (0.00\u20131.16)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.06 (0.00\u20131.16)]"
        },
        {
            "subject": {
                "study design": "ITT",
                "primary endpoint definition": "HIV infections",
                "HR": "Firth's method",
                "HR (95% CI)": "0.32 (0.01\u20139.89)",
                "p value": "0.87"
            },
            "measures": "[HR (95% CI)]",
            "outcomes": "[0.32 (0.01\u20139.89]"
        }
    ],
    "PMC10294491_2": [
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TDF-FTC",
                "No. subjects": "2693",
                "PYFU": "4386",
                "Incident HIV infections": "11"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[0.251]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TDF-FTC",
                "No. subjects": "2693",
                "PYFU": "4386",
                "Incident HIV infections": "11"
            },
            "measures": "[Rate ratio]",
            "outcomes": "[REF]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TAF-FTC",
                "No. subjects": "2694",
                "PYFU": "4370",
                "Incident HIV infections": "6"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[0.137]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TAF-FTC",
                "No. subjects": "2694",
                "PYFU": "4370",
                "Incident HIV infections": "6"
            },
            "measures": "[Rate ratio]",
            "outcomes": "[0.55 (0.20, 1.48)]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TDF-FTC",
                "PYFU": "4386",
                "Incident HIV infections": "11"
            },
            "measures": "[Averted infections]",
            "outcomes": "[79.4]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TDF-FTC",
                "PYFU": "4386",
                "Incident HIV infections": "11"
            },
            "measures": "[Averted infections ratio]",
            "outcomes": "[REF]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TAF-FTC",
                "PYFU": "4370",
                "Incident HIV infections": "6"
            },
            "measures": "[Averted infections]",
            "outcomes": "[84.0]"
        },
        {
            "subject": {
                "Trial": "DISCOVER",
                "Analysis": "primary outcome",
                "Arm": "TAF-FTC",
                "PYFU": "4370",
                "Incident HIV infections": "6"
            },
            "measures": "[Averted infections ratio]",
            "outcomes": "[1.06 (0.96\u20131.17)]"
        },
        {
            "subject": {
                "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                "Endpoints": "72"
            },
            "measures": "[HIV incidence]",
            "outcomes": "[much lower]"
        },
        {
            "subject": {
                "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                "Arm": "TDF-FTC",
                "Incident HIV infections": "11"
            },
            "measures": "[HIV incidence]",
            "outcomes": "[much lower]"
        },
        {
            "subject": {
                "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                "Arm": "TAF-FTC",
                "Incident HIV infections": "6"
            },
            "measures": "[HIV incidence]",
            "outcomes": "[much lower]"
        },
        {
            "subject": {
                "Footnote": "a",
                "Counterfactual placebo incidence rate": "2.06 per 100 PYFU"
            },
            "measures": "[Lower 2.5% credibility limit]",
            "outcomes": "[2.06]"
        }
    ],
    "PMC6158807_3": [
        {
            "subject": {
                "study type": "incidence rates of non-AIDS composite events",
                "cutoff": "CD4/CD8 ratio",
                "metric": "rate per 100 person-year",
                "confidence interval": "95% CI"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[11.42, 7.45\u201317.52]"
        },
        {
            "subject": {
                "study type": "incidence rates of non-AIDS composite events",
                "cutoff": "CD4/CD8 ratio",
                "metric": "rate per 100 person-year",
                "confidence interval": "95% CI"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[2.23, 1.77\u20132.81]"
        },
        {
            "subject": {
                "study type": "statistical significance",
                "p-value": "p < 0.001",
                "metric": "long rank test"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "CD4/CD8 ratio",
                "cutoff": "< 0.3",
                "metric": "rate per 100 person-year",
                "confidence interval": "95% CI"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[11.42, 7.45\u201317.52]"
        },
        {
            "subject": {
                "study type": "CD4/CD8 ratio",
                "cutoff": "0.30\u20130.45",
                "metric": "rate per 100 person-year",
                "confidence interval": "95% CI"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[5.64, 3.90\u20138.17]"
        },
        {
            "subject": {
                "study type": "CD4/CD8 ratio",
                "cutoff": "> 0.45",
                "metric": "rate per 100 person-year",
                "confidence interval": "95% CI"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[2.23, 1.77\u20132.81]"
        },
        {
            "subject": {
                "study type": "number of events",
                "metric": "123"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "person-year of follow-up",
                "metric": "4071"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "rate per 100 person-year",
                "metric": "3.02",
                "confidence interval": "95% CI"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[2.53\u20133.61]"
        }
    ],
    "PMC7522205_2": [
        {
            "subject": {
                "HIV-1 Genotype": "Total",
                "Patients": "%, 100.0",
                "CD4+ median": "160",
                "CD4+ IQR": "49-310"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF01_AE",
                "Patients": "%, 59.3",
                "CD4+ median": "111",
                "CD4+ IQR": "31-279"
            },
            "measures": "[Coefficient]",
            "outcomes": "[0]"
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF07_BC",
                "Patients": "%, 8.9",
                "CD4+ median": "250",
                "CD4+ IQR": "156-377"
            },
            "measures": "[Coefficient, 139]",
            "outcomes": [
                "[95% CI, (117-161)]",
                "[P, <0.001]",
                "[Adjusted Coefficient, 113]",
                "[95% CI, (86-140)]",
                "[P, <0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF08_BC",
                "Patients": "%, 25.6",
                "CD4+ median": "205",
                "CD4+ IQR": "108-327"
            },
            "measures": "[Coefficient, 94]",
            "outcomes": [
                "[95% CI, (73-115)]",
                "[P, <0.001]",
                "[Adjusted Coefficient, 80]",
                "[95% CI, (65-95)]",
                "[P, <0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "Others",
                "Patients": "%, 6.2",
                "CD4+ median": "198",
                "CD4+ IQR": "89-355"
            },
            "measures": "[Coefficient, 87]",
            "outcomes": [
                "[95% CI, (46-128)]",
                "[P, <0.001]",
                "[Adjusted Coefficient, 72]",
                "[95% CI, (37-107)]",
                "[P, <0.001]"
            ]
        }
    ],
    "PMC7414801_2": [
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "contribution percentage": "94%",
                "HIV detection visit": "HIV detection visit",
                "M3": "30%",
                "M6": "19%",
                "M9": "11%",
                "M12": "7%",
                "M15": "4%"
            },
            "measures": "[M3, M6, M9, M12, M15]",
            "outcomes": "[30%, 19%, 11%, 7%, 4%]"
        },
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "exclusion criteria": "visits following ART initiation",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "30%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "19%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "11%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "7%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "as-randomized",
                "analysis type": "continuous use",
                "participants": "382",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "4%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "continuous use",
                "analysis type": "continuous use",
                "participants": "331",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "100%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "continuous use",
                "analysis type": "continuous use",
                "participants": "331",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "30%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "continuous use",
                "analysis type": "continuous use",
                "participants": "331",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "20%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "continuous use",
                "analysis type": "continuous use",
                "participants": "331",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "12%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "continuous use",
                "analysis type": "continuous use",
                "participants": "331",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "8%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "continuous use",
                "analysis type": "continuous use",
                "participants": "331",
                "HIV detection visit": "HIV detection visit",
                "HIV VL": "4%",
                "CD4": "100%"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC9624454_2": [
        {
            "subject": {
                "Study Population": "All children",
                "Sample Size": "1024",
                "CMV Viremia": "314 (30.7)",
                "P Value": "Not reported",
                "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                "log10 CMV IU/mL in Viremics": "2.3 (1.9\u20132.7)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "Study Population": "HIV unexposed",
                "Sample Size": "872",
                "CMV Viremia": "253 (29.0)",
                "P Value": "Not reported",
                "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                "log10 CMV IU/mL in Viremics": "2.3 (1.9\u20132.7)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "Study Population": "HIV exposed",
                "Sample Size": "118",
                "CMV Viremia": "45 (38.1)",
                "P Value": "0.24",
                "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                "log10 CMV IU/mL in Viremics": "2.4 (2.0\u20132.9)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
        },
        {
            "subject": {
                "Study Population": "HIV exposed uninfected",
                "Sample Size": "97",
                "CMV Viremia": "36 (37.1)",
                "P Value": "0.74",
                "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                "log10 CMV IU/mL in Viremics": "2.4 (1.9\u20132.7)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "Study Population": "HIV infected",
                "Sample Size": "15",
                "CMV Viremia": "6 (40.0)",
                "P Value": "0.012",
                "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                "log10 CMV IU/mL in Viremics": "3.2 (2.6\u20135.3)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
        },
        {
            "subject": {
                "Citation": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                "Study Type": "Observational",
                "Population": "Hospitalized children",
                "Outcome": "CMV detection, high-level viremia, and median viral loads"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection.",
                "Study Type": "Observational",
                "Population": "Hospitalized children",
                "Outcome": "CMV detection, high-level viremia, and median viral loads"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "Footnote": "a. HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown. b. Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test. c. Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test. d. Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test.",
                "Study Type": "Observational",
                "Population": "Hospitalized children",
                "Outcome": "CMV detection, high-level viremia, and median viral loads"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
        }
    ],
    "PMC4549947_4": [
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "executive function",
                "Group": "Females",
                "Metric": "OR",
                "Outcome": "1.3"
            },
            "measures": "[OR]",
            "outcomes": "[1.3]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "executive function",
                "Group": "Males",
                "Metric": "95% CI",
                "Outcome": "1.5-5.5"
            },
            "measures": "[OR, 95% CI]",
            "outcomes": "[3.5, 1.5-5.5]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "cognitive flexibility",
                "Group": "Females",
                "Metric": "OR",
                "Outcome": "0.9"
            },
            "measures": "[OR]",
            "outcomes": "[0.9]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "cognitive flexibility",
                "Group": "Males",
                "Metric": "95% CI",
                "Outcome": "1.2-2.9"
            },
            "measures": "[OR, 95% CI]",
            "outcomes": "[1.8, 1.2-2.9]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "cognitive flexibility",
                "Group": "Hispanics",
                "Metric": "OR",
                "Outcome": "1.9"
            },
            "measures": "[OR]",
            "outcomes": "[1.9]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "cognitive flexibility",
                "Group": "African American",
                "Metric": "OR",
                "Outcome": "1.5"
            },
            "measures": "[OR]",
            "outcomes": "[1.5]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Function": "cognitive flexibility",
                "Group": "Alcohol use",
                "Metric": "OR",
                "Outcome": "1.4-2.4"
            },
            "measures": "[OR, 95% CI]",
            "outcomes": "[1.6, 1.4-2.4]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.008"
            },
            "measures": "[p-value]",
            "outcomes": "[0.008]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.01"
            },
            "measures": "[p-value]",
            "outcomes": "[0.01]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.05"
            },
            "measures": "[p-value]",
            "outcomes": "[0.05]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.01"
            },
            "measures": "[p-value]",
            "outcomes": "[0.01]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.03"
            },
            "measures": "[p-value]",
            "outcomes": "[0.03]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.013"
            },
            "measures": "[p-value]",
            "outcomes": "[0.013]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.72"
            },
            "measures": "[p-value]",
            "outcomes": "[0.72]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.32"
            },
            "measures": "[p-value]",
            "outcomes": "[0.32]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.05"
            },
            "measures": "[p-value]",
            "outcomes": "[0.05]"
        },
        {
            "subject": {
                "Metric": "p-value",
                "Outcome": "0.35"
            },
            "measures": "[p-value]",
            "outcomes": "[0.35]"
        }
    ],
    "PMC6694514_3": [
        {
            "subject": {
                "Table": "Adverse Event SOC",
                "HIV status": "HIV-positive",
                "Percentage of G3+ Events": "30.0%",
                "Total number of grade 3 or 4 adverse events": "12"
            },
            "measures": "[Percentage of G3+ Events]",
            "outcomes": "[30.0%]"
        },
        {
            "subject": {
                "Table": "Adverse Event SOC",
                "HIV status": "HIV-negative",
                "Percentage of G3+ Events": "25.0%",
                "Total number of grade 3 or 4 adverse events": "15"
            },
            "measures": "[Percentage of G3+ Events]",
            "outcomes": "[25.0%]"
        }
    ],
    "PMC6937831_2": [
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Death type": "Cancer",
                "Number of deaths": "14",
                "Percentage": "7%"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[14]"
        },
        {
            "subject": {
                "Death type": "Cancer",
                "Description": "AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
            },
            "measures": "[Description]",
            "outcomes": ""
        },
        {
            "subject": {
                "Death type": "Other diseases",
                "Description": "Unknown death categorized based on CD4 count within 6-months prior to the date of death"
            },
            "measures": "[Description]",
            "outcomes": ""
        },
        {
            "subject": {
                "Death type": "CVD",
                "Number of deaths": "12",
                "Percentage": "9%"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[12]"
        },
        {
            "subject": {
                "Death type": "Hepatic/liver-related",
                "Number of deaths": "34",
                "Percentage": "24%"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[34]"
        },
        {
            "subject": {
                "Death type": "External death",
                "Description": "Sudden death, including accident, overdose, and suicide"
            },
            "measures": "[Description]",
            "outcomes": ""
        },
        {
            "subject": {
                "Death type": "Opportunistic",
                "Number of deaths": "8",
                "Percentage": "3%"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[8]"
        },
        {
            "subject": {
                "Death type": "Other diseases",
                "Description": "The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
            },
            "measures": "[Description]",
            "outcomes": ""
        },
        {
            "subject": {
                "Death type": "Cancer",
                "Description": "Based on the CoDe protocol"
            },
            "measures": "[Description]",
            "outcomes": ""
        },
        {
            "subject": {
                "Death type": "AIDS-Related Death (ARD)",
                "Number of deaths": "241",
                "Percentage": "96%"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[241]"
        },
        {
            "subject": {
                "Death type": "AIDS-Related Death (ARD)",
                "Description": "Opportunistic"
            },
            "measures": "[Description]",
            "outcomes": ""
        }
    ],
    "PMC8340029_2": [
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "person years": "2860",
                "number of infections": "133",
                "incidence": "4.65 per 100 person-years"
            },
            "measures": "[incidence]",
            "outcomes": "[4.65 per 100 person-years]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "person years": "556",
                "number of infections": "12",
                "incidence": "2.16 per 100 person-years"
            },
            "measures": "[incidence]",
            "outcomes": "[2.16 per 100 person-years]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "person years": "2860",
                "number of infections": "133",
                "adjusted incidence rate ratio": "0.45 (0.25-0.82)"
            },
            "measures": "[adjusted incidence rate ratio]",
            "outcomes": "[0.45 (0.25-0.82)]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "person years": "556",
                "number of infections": "12",
                "adjusted incidence rate ratio": "0.45 (0.25-0.82)"
            },
            "measures": "[adjusted incidence rate ratio]",
            "outcomes": "[0.45 (0.25-0.82)]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "person years": "2860",
                "number of infections": "133",
                "p value": "0.0085"
            },
            "measures": "[p value]",
            "outcomes": "[0.0085]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "person years": "556",
                "number of infections": "12",
                "p value": "0.0085"
            },
            "measures": "[p value]",
            "outcomes": "[0.0085]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "person years": "919",
                "number of infections": "46",
                "incidence": "5.00%"
            },
            "measures": "[incidence]",
            "outcomes": "[5.00%]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "person years": "481",
                "number of infections": "11",
                "incidence": "2.29%"
            },
            "measures": "[incidence]",
            "outcomes": "[2.29%]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "person years": "919",
                "number of infections": "46",
                "adjusted incidence rate ratio": "0.44 (0.23-0.85)"
            },
            "measures": "[adjusted incidence rate ratio]",
            "outcomes": "[0.44 (0.23-0.85)]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "person years": "481",
                "number of infections": "11",
                "adjusted incidence rate ratio": "0.43 (0.22-0.83)"
            },
            "measures": "[adjusted incidence rate ratio]",
            "outcomes": "[0.43 (0.22-0.83)]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "person years": "919",
                "number of infections": "46",
                "p value": "0.015"
            },
            "measures": "[p value]",
            "outcomes": "[0.015]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "person years": "481",
                "number of infections": "11",
                "p value": "0.012"
            },
            "measures": "[p value]",
            "outcomes": "[0.012]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "before",
                "study period": "before PrEP access",
                "study site": "adjusted for",
                "randomisation group": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation group, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "after",
                "study period": "after PrEP access",
                "study site": "adjusted for",
                "randomisation arm": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "PrEP": "pre-exposure prophylaxis",
                "study": "observational"
            },
            "measures": "[study type]",
            "outcomes": "[observational]"
        },
        {
            "subject": {
                "HIV": "seroconversions",
                "study": "observational"
            },
            "measures": "[study type]",
            "outcomes": "[observational]"
        },
        {
            "subject": {
                "incidence rate ratio": "adjusted",
                "study": "observational"
            },
            "measures": "[study type]",
            "outcomes": "[observational]"
        },
        {
            "subject": {
                "p value": "study",
                "study": "observational"
            },
            "measures": "[study type]",
            "outcomes": "[observational]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access"
            },
            "measures": "[study period]",
            "outcomes": "[180 days before versus 180 days after on-site PrEP access]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "person years": "919",
                "number of infections": "46",
                "incidence": "5.00%"
            },
            "measures": "[incidence]",
            "outcomes": "[5.00%]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "person years": "481",
                "number of infections": "11",
                "incidence": "2.29%"
            },
            "measures": "[incidence]",
            "outcomes": "[2.29%]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "person years": "919",
                "number of infections": "46",
                "adjusted incidence rate ratio": "0.44 (0.23-0.85)"
            },
            "measures": "[adjusted incidence rate ratio]",
            "outcomes": "[0.44 (0.23-0.85)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "person years": "481",
                "number of infections": "11",
                "adjusted incidence rate ratio": "0.43 (0.22-0.83)"
            },
            "measures": "[adjusted incidence rate ratio]",
            "outcomes": "[0.43 (0.22-0.83)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "person years": "919",
                "number of infections": "46",
                "p value": "0.015"
            },
            "measures": "[p value]",
            "outcomes": "[0.015]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "person years": "481",
                "number of infections": "11",
                "p value": "0.012"
            },
            "measures": "[p value]",
            "outcomes": "[0.012]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study site": "adjusted for",
                "randomisation group": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation group, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation arm": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation group": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation group, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation arm": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation group": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation group, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation arm": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation group": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation group, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site",
                "study period": "180 days before versus 180 days after on-site PrEP access",
                "study site": "adjusted for",
                "randomisation arm": "adjusted for",
                "age <24 years": "adjusted for",
                "woman reporting her partner had other partners (baseline and follow-up)": "adjusted for",
                "any unprotected sex (baseline and follow-up)": "adjusted for",
                "any new partner (follow-up only)": "adjusted for"
            },
            "measures": "[adjustments]",
            "outcomes": "[study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), any new partner (follow-up only)]"
        },
        {
            "subject": {
                "study": "observational",
                "PrEP access": "on-site"
            }
        }
    ],
    "PMC8391097_3": [
        {
            "subject": {
                "PrEP status": "Overall",
                "HIV infections": "91/13 861",
                "Total follow-up": "26 210 person-years",
                "Incidence": "0.35",
                "95% CI": "0.28-0.43",
                "Citation": "Excluding patients who were diagnosed at linkage"
            },
            "measures": "[Incidence]",
            "outcomes": "[0.35]"
        },
        {
            "subject": {
                "PrEP status": "Linked but not prescribed PrEP",
                "HIV infections": "36/3013",
                "Total follow-up": "4119 person-years",
                "Incidence": "0.87",
                "95% CI": "0.63-1.21",
                "Citation": "Excluding patients who were diagnosed at linkage"
            },
            "measures": "[Incidence]",
            "outcomes": "[0.87]"
        },
        {
            "subject": {
                "PrEP status": "Prescribed PrEP but did not initiate",
                "HIV infections": "13/811",
                "Total follow-up": "1226 person-years",
                "Incidence": "1.06",
                "95% CI": "0.62-1.83",
                "Citation": "Excluding patients who were diagnosed at linkage"
            },
            "measures": "[Incidence]",
            "outcomes": "[1.06]"
        },
        {
            "subject": {
                "PrEP status": "Discontinued but reinitiated PrEP",
                "HIV infections": "4/1082",
                "Total follow-up": "1420 person-years",
                "Incidence": "0.28",
                "95% CI": "0.11-0.75",
                "Citation": "Excluding patients who were diagnosed at linkage"
            },
            "measures": "[Incidence]",
            "outcomes": "[0.28]"
        },
        {
            "subject": {
                "PrEP status": "Discontinued and did not reinitiate PrEP",
                "HIV infections": "38/2108",
                "Total follow-up": "2973 person-years",
                "Incidence": "1.28",
                "95% CI": "0.93-1.76",
                "Citation": "Excluding patients who were diagnosed at linkage"
            },
            "measures": "[Incidence]",
            "outcomes": "[1.28]"
        },
        {
            "subject": {
                "PrEP status": "Persistent on PrEP",
                "HIV infections": "0/5367",
                "Total follow-up": "9139 person-years",
                "Incidence": "0.00",
                "95% CI": "0.00-0.04",
                "Citation": "Excluding patients who were diagnosed at linkage"
            },
            "measures": "[Incidence]",
            "outcomes": "[0.00]"
        },
        {
            "subject": {
                "Citation": "Excluding patients who were diagnosed at linkage",
                "HIV incidence rate": "0.35",
                "95% CI": "0.28-0.43",
                "PrEP status": "Overall"
            },
            "measures": "[HIV incidence rate]",
            "outcomes": "[0.35]"
        },
        {
            "subject": {
                "Citation": "Excluding patients who were diagnosed at linkage",
                "HIV incidence rate": "0.87",
                "95% CI": "0.63-1.21",
                "PrEP status": "Linked but not prescribed PrEP"
            },
            "measures": "[HIV incidence rate]",
            "outcomes": "[0.87]"
        },
        {
            "subject": {
                "Citation": "Excluding patients who were diagnosed at linkage",
                "HIV incidence rate": "1.06",
                "95% CI": "0.62-1.83",
                "PrEP status": "Prescribed PrEP but did not initiate"
            },
            "measures": "[HIV incidence rate]",
            "outcomes": "[1.06]"
        },
        {
            "subject": {
                "Citation": "Excluding patients who were diagnosed at linkage",
                "HIV incidence rate": "1.28",
                "95% CI": "0.93-1.76",
                "PrEP status": "Discontinued and did not reinitiate PrEP"
            },
            "measures": "[HIV incidence rate]",
            "outcomes": "[1.28]"
        },
        {
            "subject": {
                "Citation": "Excluding patients who were diagnosed at linkage",
                "HIV incidence rate": "0.00",
                "95% CI": "0.00-0.04",
                "PrEP status": "Persistent on PrEP"
            },
            "measures": "[HIV incidence rate]",
            "outcomes": "[0.00]"
        },
        {
            "subject": {
                "Footnote": "a",
                "PrEP status": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
            },
            "measures": "[PrEP status]",
            "outcomes": "[Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage]"
        },
        {
            "subject": {
                "Footnote": "b",
                "PrEP status": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up"
            },
            "measures": "[PrEP status]",
            "outcomes": "[Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up]"
        },
        {
            "subject": {
                "Footnote": "c",
                "PrEP status": "One-sided 97.5% upper CI"
            },
            "measures": "[PrEP status]",
            "outcomes": "[One-sided 97.5% upper CI]"
        }
    ],
    "PMC8748440_2": [
        {
            "subject": {
                "Gene": "ISG15",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.29",
                "95% CI for HR": "0.11\u20130.81",
                "p value": "0.0091"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.29, 0.11\u20130.81]"
        },
        {
            "subject": {
                "Gene": "IFI6",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.18",
                "95% CI for HR": "0.037\u20130.86",
                "p value": "0.014"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.18, 0.037\u20130.86]"
        },
        {
            "subject": {
                "Gene": "IFI44L",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.55",
                "95% CI for HR": "0.27\u20131.1",
                "p value": "0.083"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.55, 0.27\u20131.1]"
        },
        {
            "subject": {
                "Gene": "IFI44",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.23",
                "95% CI for HR": "0.047\u20131.2",
                "p value": "0.045"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.23, 0.047\u20131.2]"
        },
        {
            "subject": {
                "Gene": "IFIT1",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.37",
                "95% CI for HR": "0.12\u20131.1",
                "p value": "0.054"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.37, 0.12\u20131.1]"
        },
        {
            "subject": {
                "Gene": "OAS3",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.52",
                "95% CI for HR": "0.22\u20131.3",
                "p value": "0.15"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.52, 0.22\u20131.3]"
        },
        {
            "subject": {
                "Gene": "XAF1",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.3",
                "95% CI for HR": "0.1\u20130.92",
                "p value": "0.027"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.3, 0.1\u20130.92]"
        },
        {
            "subject": {
                "Gene": "TRIM25",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.074",
                "95% CI for HR": "0.0068\u20130.8",
                "p value": "0.023"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.074, 0.0068\u20130.8]"
        },
        {
            "subject": {
                "Gene": "CMPK2",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.23",
                "95% CI for HR": "0.037\u20131.5",
                "p value": "0.074"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.23, 0.037\u20131.5]"
        },
        {
            "subject": {
                "Gene": "RSAD2",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.2",
                "95% CI for HR": "0.041\u20130.99",
                "p value": "0.032"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.2, 0.041\u20130.99]"
        },
        {
            "subject": {
                "Gene": "EIF2AK2",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.54",
                "95% CI for HR": "0.12\u20132.4",
                "p value": "0.42"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.54, 0.12\u20132.4]"
        },
        {
            "subject": {
                "Gene": "USP18",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.23",
                "95% CI for HR": "0.062\u20130.84",
                "p value": "0.022"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.23, 0.062\u20130.84]"
        },
        {
            "subject": {
                "Gene": "HERC6",
                "Module": "Module 1",
                "Analysis": "Univariable Cox regression",
                "HR": "0.16",
                "95% CI for HR": "0.019\u20131.3",
                "p value": "0.057"
            },
            "measures": "[HR, 95% CI for HR]",
            "outcomes": "[0.16, 0.019\u20131.3]"
        },
        {
            "subject": {
                "Analysis": "Multivariable Cox Regression",
                "Method": "LASSO",
                "Genes": "ISG15, TRIM25, XAF1, USP18"
            },
            "measures": "[Genes]",
            "outcomes": "[ISG15, TRIM25, XAF1, USP18]"
        },
        {
            "subject": {
                "Module": "Module 1",
                "Description": "Hub genes identified by the WGCNA analysis"
            },
            "measures": "[Description]",
            "outcomes": "[Hub genes identified by the WGCNA analysis]"
        },
        {
            "subject": {
                "Citation": "As a next step, we looked to see if any of the individual hub genes identified in the WGCNA results were more closely linked to progression, potentially leading to a signature that might predict longer post-TI viral suppression"
            },
            "measures": "[Citation]",
            "outcomes": "[As a next step, we looked to see if any of the individual hub genes identified in the WGCNA results were more closely linked to progression, potentially leading to a signature that might predict longer post-TI viral suppression]"
        }
    ],
    "PMC7615197_2": [
        {
            "subject": {
                "Study arm": "Dexamethasone",
                "Number of patients": "263",
                "Number of deaths": "116",
                "Hazard ratio": "0.85",
                "95% confidence interval": "0.66-1.10",
                "P value": "0.22",
                "Test for proportional hazards": "0.36"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[0.85]"
        },
        {
            "subject": {
                "Study arm": "Placebo",
                "Number of patients": "257",
                "Number of deaths": "126",
                "Hazard ratio": "0.85",
                "95% confidence interval": "0.66-1.10",
                "P value": "0.22",
                "Test for proportional hazards": "0.36"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[0.85]"
        },
        {
            "subject": {
                "Sub-group": "Grade I",
                "Number of patients": "99",
                "Number of deaths": "22",
                "Hazard ratio": "0.72",
                "95% confidence interval": "0.41-1.25",
                "P value": "0.24",
                "Test for proportional hazards": "0.15"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[0.72]"
        },
        {
            "subject": {
                "Sub-group": "Grade II",
                "Number of patients": "125",
                "Number of deaths": "60",
                "Hazard ratio": "0.82",
                "95% confidence interval": "0.58-1.16",
                "P value": "0.27",
                "Test for proportional hazards": "0.57"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[0.82]"
        },
        {
            "subject": {
                "Sub-group": "Grade III",
                "Number of patients": "39",
                "Number of deaths": "34",
                "Hazard ratio": "1.11",
                "95% confidence interval": "0.70-1.77",
                "P value": "0.65",
                "Test for proportional hazards": "0.89"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[1.11]"
        },
        {
            "subject": {
                "Population": "Intention-to-treat",
                "Number of patients": "263",
                "Number of deaths": "116",
                "Hazard ratio": "0.85",
                "95% confidence interval": "0.66-1.10",
                "P value": "0.22",
                "Test for proportional hazards": "0.36"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[0.85]"
        },
        {
            "subject": {
                "Population": "Per-protocol",
                "Number of patients": "263",
                "Number of deaths": "116",
                "Hazard ratio": "0.85",
                "95% confidence interval": "0.66-1.10",
                "P value": "0.22",
                "Test for proportional hazards": "0.36"
            },
            "measures": "[Hazard ratio]",
            "outcomes": "[0.85]"
        }
    ],
    "PMC9008168_2": [
        {
            "subject": {
                "HIV status": "without HIV",
                "ART status": "none",
                "Incidence rate type": "unadjusted",
                "BMI": "\u226525 kg/m\u00b2",
                "Incidence rate": "69.8",
                "95% CI": "Reference",
                "HR": "1.00"
            },
            "measures": "[Incidence rate, HR]",
            "outcomes": "[69.8, 1.00]"
        },
        {
            "subject": {
                "HIV status": "with HIV",
                "ART status": "non-TLD ART",
                "Incidence rate type": "unadjusted",
                "BMI": "\u226525 kg/m\u00b2",
                "Incidence rate": "77.1",
                "95% CI": "0.79\u20131.63",
                "HR": "1.13"
            },
            "measures": "[Incidence rate, HR]",
            "outcomes": "[77.1, 1.13]"
        },
        {
            "subject": {
                "HIV status": "with HIV",
                "ART status": "TLD",
                "Incidence rate type": "unadjusted",
                "BMI": "\u226525 kg/m\u00b2",
                "Incidence rate": "73.3",
                "95% CI": "1.22\u20132.55",
                "HR": "1.77"
            },
            "measures": "[Incidence rate, HR]",
            "outcomes": "[73.3, 1.77]"
        },
        {
            "subject": {
                "HIV status": "with HIV",
                "ART status": "ART na\u00efve",
                "Incidence rate type": "unadjusted",
                "BMI": "\u226525 kg/m\u00b2",
                "Incidence rate": "37.7",
                "95% CI": "0.27\u20130.70",
                "HR": "0.43"
            },
            "measures": "[Incidence rate, HR]",
            "outcomes": "[37.7, 0.43]"
        },
        {
            "subject": {
                "Citation": "Of the 2144 participants at risk",
                "BMI": "\u226525 kg/m\u00b2",
                "Number of participants": "516"
            },
            "measures": "[Number of participants]",
            "outcomes": "[516]"
        },
        {
            "subject": {
                "Caption": "Unadjusted incidence rates and hazard ratios (HR) of BMI \u226525 kg/m\u00b2 by HIV and ART status"
            },
            "measures": "[Caption]",
            "outcomes": "[Unadjusted incidence rates and hazard ratios (HR) of BMI \u226525 kg/m\u00b2 by HIV and ART status]"
        },
        {
            "subject": {
                "Footnote": "Abbreviations: PLWH, people living with HIV; TLD, tenofovir/lamivudine/dolutegravir; PY, person-years"
            },
            "measures": "[Footnote]",
            "outcomes": "[Abbreviations: PLWH, people living with HIV; TLD, tenofovir/lamivudine/dolutegravir; PY, person-years]"
        },
        {
            "subject": {
                "Text": "Unadjusted incidence rates of developing a high BMI were similar among participants without HIV and those on ART with the highest incidence among participants on non-TLD ART"
            },
            "measures": "[Text]",
            "outcomes": "[Unadjusted incidence rates of developing a high BMI were similar among participants without HIV and those on ART with the highest incidence among participants on non-TLD ART]"
        }
    ],
    "PMC7644038_3": [
        {
            "subject": {
                "Health Condition": "Depression",
                "HIV Status": "HIV",
                "Age": "65",
                "Year": "2011-2016",
                "Beneficiaries": "Medicare",
                "Unadjusted": "Yes"
            },
            "measures": "[Prevalence, Percent difference, Odds ratio]",
            "outcomes": "[24.3%, 291.9%, 2.29]"
        },
        {
            "subject": {
                "Health Condition": "Chronic kidney disease",
                "HIV Status": "HIV",
                "Age": "65",
                "Year": "2011-2016",
                "Beneficiaries": "Medicare",
                "Unadjusted": "Yes"
            },
            "measures": "[Prevalence, Percent difference, Odds ratio]",
            "outcomes": "[46.2%, 144.4%, 1.92]"
        },
        {
            "subject": {
                "Health Condition": "Depression",
                "HIV Status": "No HIV",
                "Age": "65",
                "Year": "2011-2016",
                "Beneficiaries": "Medicare",
                "Unadjusted": "Yes"
            },
            "measures": "[Prevalence, Percent difference, Odds ratio]",
            "outcomes": "[6.2%, -%, -]"
        },
        {
            "subject": {
                "Health Condition": "Chronic kidney disease",
                "HIV Status": "No HIV",
                "Age": "65",
                "Year": "2011-2016",
                "Beneficiaries": "Medicare",
                "Unadjusted": "Yes"
            },
            "measures": "[Prevalence, Percent difference, Odds ratio]",
            "outcomes": "[18.9%, -%, -]"
        },
        {
            "subject": {
                "Citation": "People with HIV",
                "Health Condition": "All",
                "Age": "65",
                "Year": "2011-2016",
                "Beneficiaries": "Medicare",
                "Unadjusted": "Yes"
            },
            "measures": "[Rates, -]",
            "outcomes": "[higher overall rates]"
        },
        {
            "subject": {
                "Caption": "Prevalence",
                "Health Condition": "-",
                "Age": "-",
                "Year": "-",
                "Beneficiaries": "-",
                "Unadjusted": "-"
            },
            "measures": "[Means, Odds ratios]",
            "outcomes": "[reported]"
        },
        {
            "subject": {
                "Footnote": "Significance",
                "Health Condition": "-",
                "Age": "-",
                "Year": "-",
                "Beneficiaries": "-",
                "Unadjusted": "-"
            },
            "measures": "[p-value, -]",
            "outcomes": "[*** p-value<0.001, ** p-value < 0.01, * p-value < 0.05]"
        },
        {
            "subject": {
                "Footnote": "Controls",
                "Health Condition": "-",
                "Age": "-",
                "Year": "-",
                "Beneficiaries": "-",
                "Unadjusted": "-"
            },
            "measures": "[Variables, -]",
            "outcomes": "[age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid]"
        },
        {
            "subject": {
                "Footnote": "Weighting",
                "Health Condition": "-",
                "Age": "-",
                "Year": "-",
                "Beneficiaries": "-",
                "Unadjusted": "-"
            },
            "measures": "[Method, -]",
            "outcomes": "[probability weights]"
        },
        {
            "subject": {
                "Footnote": "Confidence intervals",
                "Health Condition": "-",
                "Age": "-",
                "Year": "-",
                "Beneficiaries": "-",
                "Unadjusted": "-"
            },
            "measures": "[95%, -]",
            "outcomes": "[reported in parentheses]"
        }
    ],
    "PMC6033411_2": [
        {
            "subject": {
                "study": "HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "number of participants": "200",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "characteristic": "demographic",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[total number, clustered, odds ratio, p-value]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "age": "years",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[15 and younger, 34.5%, 37.3%, 1.0, ...]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "age": "years",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[16, 23%, 22%, 0.84, 0.67]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "age": "years",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[17+, 42.5%, 40.7%, 0.87, 0.69]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "household income": "R",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[<999, 30.5%, 37.3%, 1.0, ...]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "household income": "R",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[10,000\u201399,000, 56%, 45.8%, 0.56, 0.1]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "household income": "R",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[>100,000, 12.5%, 16.9%, 1.04, 0.93]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "CD4 cell count": "cells/mm<sup>3</sup>",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[>500, 46%, 50.9%, 1.0, ...]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "CD4 cell count": "cells/mm<sup>3</sup>",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[&le;500, 37.5%, 32.2%, 0.70, 0.31]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "CD4 cell count": "cells/mm<sup>3</sup>",
                "study population": "200 HIV-infected study participants",
                "genetic distance threshold": "4.5%",
                "clustering type": "phylogenetic clustering"
            },
            "measures": "[&le;250, 7.5%, 6.8%, 0.75, 0.65]",
            "outcomes": "[]"
        }
    ]
}